French biopharma company Sanofi has inaugurated a new $661 million flu vaccine production facility in Toronto, Canada, making it the largest biopharma manufacturing site in the country and representing the single largest biomanufacturing investment in Canadian history — including $296 million in federal government support and $39 million from the province of Ontario.

Located on the company’s 52-acre Toronto campus, the 194,000-square-foot Charles Best Building — which is fully operational and pending regulatory approval — will produce antigen for Sanofi’s Fluzone high-dose influenza vaccine for adults 65 years of age and older in Canada and other countries. 

Named after Dr. Charles Best, co-discoverer of insulin and early medical director at what is now Sanofi’s Toronto campus, the building is the “anchor facility” in an end-to-end influenza vaccine production chain, which spans drug substance, formulation, filling, inspection, and packaging, according to the company.

Brendan O’Callaghan, global executive vice president of manufacturing and supply at Sanofi, said during a press conference that the new facility brings domestic flu vaccine manufacturing capacity to Canada and strengthens pandemic readiness on Canadian soil.

“The Charles Best Building marks an important new chapter in Canada’s public health leadership with this state-of-the-art facility representing the latest in high-quality biomanufacturing capability to support the delivery of differentiated, high-dose influenza vaccines,” O’Callaghan said, noting Sanofi’s 70 years of experience developing and manufacturing flu vaccines. 

Together, the buildings on the Toronto campus will be the largest end-to-end vaccine production facility in Canada, leveraging digital systems including artificial intelligence (AI), real-time process control, batch execution, and operational analytics to increase manufacturing efficiency, according to Sanofi.

Canada’s largest biopharma manufacturer

Sanofi’s latest investment aligns with the company’s broader commitment to Canada. The company will make more than $2 billion in new infrastructure investments by 2028 across its Toronto campus, including a 270,000-square-foot pediatric and booster vaccine plant. Sanofi contends it is the largest biopharma manufacturer in the country, with more than 2,000 employees.

“We selected Canada for this major investment because of the country’s world-class scientific talent and research ecosystem,” O’Callaghan said, adding that “the world and the times in which we decided this investment looks very different today than when we first broke ground almost 10 years ago.” 

As the head of Sanofi’s manufacturing and supply organization, O’Callaghan observed the “landscape for life sciences development is changing fundamentally and rapidly in front of our eyes.” He warned the global supply chains “that we built and relied over the last 40 and 50 years — and that we somehow took for granted — have proven to be fragile.”

O’Callaghan made the case that “scientific progress, government investment around the world, and geopolitical shifts are redrawing the map of where new medicines and vaccines are being discovered, developed, and ultimately where they’ll be produced to meet the long-term needs of population health.”  

In May, Sanofi announced a $294 million investment in the expansion of its global Artificial Intelligence Center of Excellence in Toronto, leading the design and deployment of AI in Sanofi’s global research, manufacturing, and business operations. Created in 2022, the center co-locates data, AI, scientific, manufacturing, and product teams in a single location to help drive innovation “from molecule to medicine and from antigen to vaccine” across the “full life sciences” value chain, according to Sanofi.

With a global network of close to 40 internal manufacturing sites, Sanofi manufactures more than 250 million vaccine doses globally at production sites in Argentina, Canada, China, France, Mexico, and the United States.

However, manufacturing resilience is a priority for governments just as much as it is for biopharma companies such as Sanofi, O’Callaghan said.

“The path forward requires sustained partnership between government and industry — not transactional, not short term, but partnership that’s built on shared commitment to long-term science-based innovation for patients,” he concluded.